Compare, Analyse Dishman Pharma with ACTAVIS INC. - US - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

DISHMAN PHARMA vs ACTAVIS (US) - Comparison Results

DISHMAN PHARMA     Change

Dishman Pharmaceuticals is involved in the manufacture of APIs (active pharmaceutical ingredients), intermediates, quaternary compounds and fine chemicals. Besides this, the company is a significant player in the CRAMS (Contract Research and Manufact... More

ACTAVIS (US)
   Change

Actavis, Inc. is a global, integrated specialty pharmaceutical company focused on developing, manufacturing and distributing generic, brand and biosimilar products. It develops, manufactures and market generic, branded generic, legacy brands and Over... More

DO YOU LIKE THESE REPORTS? TELL US!

Financials

 DISHMAN PHARMA   ACTAVIS
EQUITY SHARE DATA
    DISHMAN PHARMA
Mar-16
ACTAVIS
Dec-18
DISHMAN PHARMA/
ACTAVIS
5-Yr Chart
Click to enlarge
High Rs37414,478-   
Low Rs1299,712-   
Sales per share (Unadj.) Rs197.83,551.4-  
Earnings per share (Unadj.) Rs21.2-1,143.9-  
Cash flow per share (Unadj.) Rs34.7374.2-  
Dividends per share (Unadj.) Rs2.000-  
Dividend yield (eoy) %0.80-  
Book value per share (Unadj.) Rs179.914,647.7-  
Shares outstanding (eoy) m80.69332.60-   
Bonus/Rights/Conversions ---  
Price / Sales ratio x1.33.4 37.4%   
Avg P/E ratio x11.9-10.6 -112.2%  
P/CF ratio (eoy) x7.232.3 22.4%  
Price / Book Value ratio x1.40.8 169.4%  
Dividend payout %9.40-   
Avg Mkt Cap Rs m20,3064,022,682 0.5%   
No. of employees `0000.816.9 4.9%   
Total wages/salary Rs m5,3550-   
Avg. sales/employee Rs Th19,252.769,892.5 27.5%   
Avg. wages/employee Rs Th6,459.50-   
Avg. net profit/employee Rs Th2,064.1-22,512.4 -9.2%   
INCOME DATA
Net Sales Rs m15,9611,181,183 1.4%  
Other income Rs m26522,588 1.2%   
Total revenues Rs m16,2261,203,771 1.3%   
Gross profit Rs m4,10330,953 13.3%  
Depreciation Rs m1,091504,930 0.2%   
Interest Rs m94468,161 1.4%   
Profit before tax Rs m2,334-519,550 -0.4%   
Minority Interest Rs m00-   
Prior Period Items Rs m10-   
Extraordinary Inc (Exp) Rs m0132,506 0.0%   
Tax Rs m624-6,584 -9.5%   
Profit after tax Rs m1,711-380,460 -0.4%  
Gross profit margin %25.72.6 981.0%  
Effective tax rate %26.71.3 2,108.7%   
Net profit margin %10.7-32.2 -33.3%  
BALANCE SHEET DATA
Current assets Rs m11,018484,460 2.3%   
Current liabilities Rs m9,517428,569 2.2%   
Net working cap to sales %9.44.7 198.7%  
Current ratio x1.21.1 102.4%  
Inventory Days Days11020 564.2%  
Debtors Days Days3566 52.5%  
Net fixed assets Rs m16,304133,703 12.2%   
Share capital Rs m1610-   
"Free" reserves Rs m12,9070-   
Net worth Rs m14,5164,871,829 0.3%   
Long term debt Rs m4,1891,715,548 0.2%   
Total assets Rs m29,8057,615,778 0.4%  
Interest coverage x3.5-6.6 -52.4%   
Debt to equity ratio x0.30.4 82.0%  
Sales to assets ratio x0.50.2 345.3%   
Return on assets %8.9-4.1 -217.3%  
Return on equity %11.8-7.8 -150.9%  
Return on capital %17.5-4.8 -362.1%  
Exports to sales %24.80-   
Imports to sales %3.70-   
Net fx Rs m4,2550-   
CASH FLOW
From Operations Rs m2,786421,992 0.7%  
From Investments Rs m-1,529231,830 -0.7%  
From Financial Activity Rs m-941-724,265 0.1%  
Net Cashflow Rs m316-70,091 -0.5%  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster
The reporting currency for ACTAVIS (US) is United States Dollars. All data has been converted at 74.82 Rs / USD

Compare DISHMAN PHARMA With: ADCOCK INGRAM (S. Africa)  MYLAN (US)  TEVA PHARMA (Israel)  

Compare DISHMAN PHARMA With: SHASUN PHARMA  NEULAND LABS  GSK PHARMA  PANACEA BIOTECH  TTK HEALTHCARE  



Today's Market

Sensex Ends Flat; Wipro & Hindalco Industries Among Top Nifty Gainers(Closing)

Indian share markets witnessed volatile trading activity throughout the day today and ended on a flat note.

Related Views On News

Most Popular

India: Recovery Stalled by Vaccine Games? (The Honest Truth)

Apr 13, 2021

Ajit Dayal on how India's vaccine strategy will impact the markets.

4 Stocks to Make Your Portfolio Immune to the Second Covid Wave (Profit Hunter)

Apr 6, 2021

Rather than predicting the market, successful investing is more about preparing well and placing your bets accordingly.

An India Revival Stock I'm Bullish On... (Profit Hunter)

Apr 9, 2021

This could take India to the position of 3rd largest economy.

Why Did the Market Crash on Monday? (Fast Profits Daily)

Apr 13, 2021

In this video, I'll you what I think is the real reason behind yesterday's market crash.

Why the Market Fell Yesterday (Fast Profits Daily)

Apr 6, 2021

In this video, I'll tell you the two reasons why the market fell on Monday and how you can prepare yourself for such events in the future.

More
-->

India's #1 Trader
Reveals His Secrets

Secret To Increasing Your Trading Profits Today
Get this Special Report,
The Secret to Increasing Your Trading Profits Today, Now!
We will never sell or rent your email id.
Please read our Terms

OUR TOP 5 IDEAS

Free Report: Multibagger Stock Ideas 2021
Are You Making One of These 15 Costly Mistakes While Investing. Learn more!
Covid-19 Proof Multibagger Stocks - Download this FREE Report Now
Free Report: The Secret to Increasing Your Trading Profits Daily!
No Guessing, No Hunches, and No Missed Trends Ever! Join Us on YouTube Now.

DISHMAN PHARMA SHARE PRICE


May 29, 2017 (Close)

TRACK DISHMAN PHARMA

  • Track your investment in DISHMAN PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON DISHMAN PHARMA

DISHMAN PHARMA 8-QTR ANALYSIS

COMPARE DISHMAN PHARMA WITH

FEATURED VIDEOS

Market Crash: Picture Abhi Baaki Hai?

It's a Great Time to Buy Gold

The Dilemma of Investing in Bharti Airtel

Nifty: Bear Trap?

More Featured Videos

MARKET STATS